genOway Société anonyme

ENXTPA:ALGEN Stock Report

Market Cap: €31.0m

genOway Société anonyme Valuation

Is ALGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALGEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALGEN's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALGEN?

Other financial metrics that can be useful for relative valuation.

ALGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA5.9x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does ALGEN's PE Ratio compare to its peers?

The above table shows the PE ratio for ALGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average17.2x
OSE OSE Immunotherapeutics
4.8x-72.4%€222.8m
GNFT Genfit
12.1x35.6%€269.0m
ALERS Eurobio Scientific Société anonyme
39.1x29.0%€259.6m
ALECR Eurofins-Cerep
12.7xn/a€97.3m
ALGEN genOway Société anonyme
24.7xn/a€31.0m

Price-To-Earnings vs Peers: ALGEN is expensive based on its Price-To-Earnings Ratio (24.7x) compared to the peer average (17.2x).


Price to Earnings Ratio vs Industry

How does ALGEN's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a8.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a8.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: ALGEN is expensive based on its Price-To-Earnings Ratio (24.7x) compared to the European Biotechs industry average (24.3x).


Price to Earnings Ratio vs Fair Ratio

What is ALGEN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALGEN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ALGEN's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies